Zachary T. Bloomgarden, MD, MACE: We somewhat arbitrarily have divided the complications of type 2 diabetes into 2 groups: microvascular—referring to small vessel abnormalities [such as] diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy; and macrovascular—referring to atherosclerotic cardiovascular disease. These are the major complications of diabetes and affect a huge proportion of individuals with the disease.
We understand type 2 diabetes as representing the intersection of both genetically and environmentally determined patient characteristics. One is insulin resistance—decreased action of insulin at its receptor. That is caused by the environment, namely obesity, lack of physical activity, and a number of genetic factors, as well.
Then, [another characteristic is] reduction in the insulin secretory response to various stimuli, and this is probably primarily a genetic factor. So, in this context, the insulin secretory effect is not directly related to the other aspects of metabolic syndrome. But metabolic syndrome is essentially a constellation of abnormalities that are all related to insulin resistance. This is what seems to be the central actor that leads to hypertension, that leads to a certain form of dyslipidemia caused by obesity (particularly abdominal obesity), which then leads to the concurrence of diabetes with the other cardiovascular risk factors.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More